Base de dados : MEDLINE
Pesquisa : C12.777.419.570.363.608 [Categoria DeCS]
Referências encontradas : 5443 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 545 ir para página                         

  1 / 5443 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397599
[Au] Autor:Chen Z; Yang YJ; Li J; Tian XP
[Ad] Endereço:Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
[Ti] Título:[The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].
[So] Source:Zhonghua Nei Ke Za Zhi;57(2):129-133, 2018 Feb 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the clinical features of Takayasu's arteritis (TAK) with glomerulonephropathy and to improve physicians' understanding of this complication in patients with TAK. Clinical data were retrospectively collected including manifestations, laboratory tests, image findings and treatment of 8 patients diagnosed as Takayasu's arteritis with glomerulonephropathy from January 2002 to January 2017 in Peking Union Medical College Hospital. Glomerulonephropathy was confirmed based on percutaneous renal biopsy. There were 6 women and 2 men. The median onset age and median disease duration were 24 (18-37) years and 42 (3-360) months, respectively. Five patients had hypertension. The 24 hour urinary protein was 0.18-14.91 g. Red blood cells and casts in urine were tested among 4 and 2 patients, respectively. Three patients had renal artery stenosis. Three patients demonstrated mesangial proliferative glomerulonephritis, two with IgA nephropathy, two with minimal change disease and one with membranoproliferative glomerulonephritis. Seven patients received glucocorticoid combined with cyclophosphamide therapy (glucocorticoid 40-60 mg/d, prednisone or equivalent; cyclophosphamide 0.4 g/week iv. or cyclophosphamide 0.1 g/d po.). Uninary blood cells removed and 24 hour urinary protein decreased from 1.65 g to 0.90 g after treatment for 12 months in one patient. The other 7 patients were missing. Glomerulonephropathy is occasionally observed among TAK patients. Mesangial proliferative glomerulonephritis is the most common pathological subtype. Glucocorticoid combined with cyclophosphamide therapy could be an optional therapy for Takayasu's arteritis with glomerulonephropathy.
[Mh] Termos MeSH primário: Glomerulonefrite Membranoproliferativa/etiologia
Glomerulonefrite/etiologia
Arterite de Takayasu/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Ciclofosfamida/administração & dosagem
Ciclofosfamida/uso terapêutico
Eritrócitos
Feminino
Glomerulonefrite/patologia
Glomerulonefrite por IGA
Glomerulonefrite Membranoproliferativa/patologia
Glucocorticoides/administração & dosagem
Glucocorticoides/uso terapêutico
Seres Humanos
Hipertensão
Masculino
Prednisona/administração & dosagem
Prednisona/uso terapêutico
Arterite de Takayasu/complicações
Arterite de Takayasu/tratamento farmacológico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.02.009


  2 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29182841
[Au] Autor:Inanaga R; Shimizu H; Uchida H; Kataoka I; Kobayashi M; Fukuoka K; Karube M; Komagata Y; Kaname S; Arimura Y
[Ti] Título:[A case report of a nephrotic syndrome on IgA nephropathy complicated by Kimura's disease.]
[So] Source:Nihon Naika Gakkai Zasshi;105(5):881-885, 2016 May.
[Is] ISSN:0021-5384
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Hiperplasia Angiolinfoide com Eosinofilia/complicações
Glomerulonefrite por IGA/complicações
Síndrome Nefrótica/etiologia
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  3 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29199436
[Au] Autor:Nagy J; Sági B; Máté J; Vas T; Kovács T
[Ad] Endereço:Klinikai Központ, II. Belgyógyászati Klinika és Nefrológiai Centrum, Pécsi Tudományegyetem, Általános Orvostudományi Kar Pécs, Pacsirta u. 1., 7624.
[Ti] Título:[Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
[Ti] Título:Terápiás megfontolások IgA-nephropathiában a legutolsó vizsgálatok (STOP-IgAN, TESTING, NEFIGAN) eredményei alapján..
[So] Source:Orv Hetil;158(49):1946-1952, 2017 Dec.
[Is] ISSN:0030-6002
[Cp] País de publicação:Hungary
[La] Idioma:hun
[Ab] Resumo:IgA nephropathy is an immune-mediated chronic glomerulonephritis with a great variability in clinical presentation and outcome. The disease can progress to end-stage renal failure in 25% of patients. For this reason we should identify patients with potential to progress. Most important risk factors for progression are persistent proteinuria, hypertension, decreased renal function and some histological lesions. The actually suggested treatment is summarized in KDIGO Clinical Practice Guideline from 2012. They suggest to give firstly non-specific supportive treatment (especially renin-angiotensin system blocking agents). Recommendation about steroid/immunosuppression treatment is based on low level of evidence. Recently three studies were organised concerning benefits and risk of steroid/immunosuppressive treatment added together with specific supportive treatment. In the STOP-IgAN study, systemic steroid/immunosuppressive treatment significantly decreased proteinuria but did not stop progression. In the TESTING study, systemic steroid treatment significantly decreased proteinuria and progression. However, the study was recently discontinued due to several severe side effects of steroid treatment. Involvement of intestinal mucosal immunity in the pathogenesis of IgA nephropathy suggested the NEFIGAN study with budesonide treatment. Budesonide releases corticosteroid in distal small intestine and colon. Proteinuria was significantly decreased and renal function remained stabile. High number of withdrawals owing to adverse effects is a major concern implying a substantial systemic effect of budesonide. We need further information on the characteristics of patients who most likely benefit from steroid/immunosuppressive treatment given after or together with specific supportive treatment. Orv Hetil. 2017; 158(49): 1946-1952.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/tratamento farmacológico
Imunossupressores/uso terapêutico
Falência Renal Crônica/prevenção & controle
[Mh] Termos MeSH secundário: Budesonida/efeitos adversos
Budesonida/uso terapêutico
Procedimentos Clínicos
Taxa de Filtração Glomerular
Glomerulonefrite por IGA/imunologia
Seres Humanos
Imunossupressão
Falência Renal Crônica/tratamento farmacológico
Proteinúria/tratamento farmacológico
Proteinúria/imunologia
Medição de Risco
Esteroides/efeitos adversos
Esteroides/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Steroids); 51333-22-3 (Budesonide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1556/650.2017.30924


  4 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324897
[Au] Autor:Placzek WJ; Yanagawa H; Makita Y; Renfrow MB; Julian BA; Rizk DV; Suzuki Y; Novak J; Suzuki H
[Ad] Endereço:Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
[Ti] Título:Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.
[So] Source:PLoS One;13(1):e0190967, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:IgA nephropathy is an autoimmune disease characterized by IgA1-containing glomerular immune deposits. We previously proposed a multi-hit pathogenesis model in which patients with IgA nephropathy have elevated levels of circulatory IgA1 with some O-glycans deficient in galactose (Gd-IgA1, autoantigen). Gd-IgA1 is recognized by anti-glycan IgG and/or IgA autoantibodies, resulting in formation of pathogenic immune complexes. Some of these immune complexes deposit in the kidney, activate mesangial cells, and incite glomerular injury leading to clinical presentation of IgA nephropathy. Several studies have demonstrated that elevated circulatory levels of either Gd-IgA1 or the corresponding autoantibodies predict progressive loss of renal clearance function. In this study we assessed a possible association between serum levels of Gd-IgA1 and IgG or IgA autoantibodies specific for Gd-IgA1 in serum samples from 135 patients with biopsy-proven IgA nephropathy, 76 patients with other renal diseases, and 106 healthy controls. Our analyses revealed a correlation between the concentrations of the autoantigen and the corresponding IgG autoantibodies in sera of patients with IgA nephropathy, but not of disease or healthy controls. Moreover, our data suggest that IgG is the predominant isotype of Gd-IgA1-specific autoantibodies in IgA nephropathy. This work highlights the importance of both initial hits in the pathogenesis of IgA nephropathy.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Glomerulonefrite por IGA/sangue
Imunoglobulina A/sangue
Imunoglobulina G/sangue
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Estudos de Coortes
Ensaio de Imunoadsorção Enzimática
Glomerulonefrite por IGA/patologia
Seres Humanos
Insuficiência Renal Crônica/sangue
Insuficiência Renal Crônica/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers); 0 (Immunoglobulin A); 0 (Immunoglobulin G)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190967


  5 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202533
[Au] Autor:Xu J; Hu XF; Huang W; Shen PY; Zhang W; Ren H; Li X; Wang WM; Chen N; Pan XX
[Ad] Endereço:Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
[Ti] Título:[The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients].
[So] Source:Zhonghua Nei Ke Za Zhi;56(12):924-929, 2017 Dec 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the clinicopathological characteristics of renal lesions in type 2 diabetic patients and to differentiate diabetic nephropathy (DN) from non-diabetic renal diseases(NDRD). Type 2 diabetic patients who received renal biopsy in Ruijin Hospital from January 2011 to December 2015 were recruited in this study. Clinical history, laboratory results and pathological data were retrospectively collected. According to the pathological findings, the patients were divided into 3 groups: DN, NDRD, DN+NDRD. Logistic model was applied to explore the independent clinical predictive factors in differentiating DN from NDRD. A total of 207 type 2 diabetic patients received renal biopsy, accounting for 6.82% of all biopsy population. Fifty-one patients were diagnosed with DN, 142 with NDRD and 14 with both DN and NDRD. In NDRD, membranous nephropathy(MN)(34.5%) was the most common finding, followed by IgA nephropathy(19.7%).By contrast, NDRD patients manifested a shorter diabetic course, a higher baseline hemoglobin level, a lower baseline serum creatinine, a higher prevalence of hematuria, a lower prevalence of hypertension and diabetic retinopathy, a better control of blood glucose, better compliance of monitoring blood glucose and less family history of diabetes. In multivariate logistic model, diabetic family history( 4.68, 0.04) and long history of diabetes( 1.01, 0.02) were risk factors of DN. There is a high prevalence of NDRD in diabetic patients with renal lesions. Family history of diabetes and duration of diabetes are independent predictors of DN.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/patologia
Nefropatias Diabéticas/patologia
Taxa de Filtração Glomerular/fisiologia
Nefropatias/patologia
Rim/patologia
[Mh] Termos MeSH secundário: Biópsia
China/epidemiologia
Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/epidemiologia
Nefropatias Diabéticas/epidemiologia
Nefropatias Diabéticas/etiologia
Feminino
Glomerulonefrite por IGA/epidemiologia
Glomerulonefrite Membranosa/epidemiologia
Hematúria/epidemiologia
Seres Humanos
Hipertensão/epidemiologia
Rim/fisiopatologia
Nefropatias/epidemiologia
Nefropatias/etiologia
Modelos Logísticos
Masculino
Meia-Idade
Prevalência
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.12.007


  6 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245330
[Au] Autor:Ahn JH; Kim JS; Choi JH; Chung JH
[Ad] Endereço:aDepartment of Internal Medicine, Regional Center for Respiratory Disease, Yeungnam University Medical CenterbDepartment of Pathology, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
[Ti] Título:A first case report of pulmonary hyalinizing granuloma associated with immunoglobulin A nephropathy.
[So] Source:Medicine (Baltimore);96(49):e9088, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Pulmonary hyalinizing granuloma (PHG) is a rare benign disease that has been shown to be associated with the deposition of immune complexes in the lung parenchyma caused by infection or autoimmune diseases. There have been no reports of PHG in association with immunoglobulin A nephropathy (IgAN). PATIENT CONCERNS: A 30-year-old woman visited with a 12-month history of dyspnea on exertion and cough that had worsened 1 month before her visit. DIAGNOSIS: PHG associated with IgAN. INTERVENTIONS: Steroid pulse therapy was performed. OUTCOMES: The patient was discharged uneventfully. LESSONS: We present a case of PHG presenting as multiple pulmonary nodules mimicking metastatic lung cancer, which was diagnosed using wedge resection of the right middle lobe through video-assisted thoracoscopic surgery.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/complicações
Granuloma/patologia
Pneumopatias/patologia
[Mh] Termos MeSH secundário: Adulto
Broncoscopia
Terapia Combinada
Meios de Contraste
Diagnóstico Diferencial
Feminino
Granuloma/diagnóstico por imagem
Granuloma/tratamento farmacológico
Granuloma/cirurgia
Seres Humanos
Biópsia Guiada por Imagem
Pneumopatias/diagnóstico por imagem
Pneumopatias/tratamento farmacológico
Pneumopatias/cirurgia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Testes de Função Respiratória
Esteroides/uso terapêutico
Cirurgia Torácica Vídeoassistida
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media); 0 (Steroids)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009088


  7 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28763548
[Au] Autor:Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V; TESTING Study Group
[Ad] Endereço:Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China2The George Institute for Global Health, University of New South Wales, Sydney, Australia.
[Ti] Título:Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
[So] Source:JAMA;318(5):432-442, 2017 08 01.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. Objective: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. Design, Setting, and Participants: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred. Interventions: Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8 mg/kg/d; maximum, 48 mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent weaning over 4 to 6 months. Main Outcomes and Measures: The primary composite outcome was end-stage kidney disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis, and cardiovascular events. The mean required follow-up was estimated to be 5 years. Results: After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%] women; eGFR, 59.4 mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years' median follow-up, recruitment was discontinued because of excess serious adverse events. Serious events occurred in 20 participants (14.7%) in the methylprednisolone group vs 4 (3.2%) in the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%]; P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in the methylprednisolone group vs 20 (15.9%) in the placebo group (hazard ratio, 0.37 [95% CI, 0.17-0.85]; risk difference, 10.0% [95% CI, 2.5%-17.9%]; P = .02). Conclusions and Relevance: Among patients with IgA nephropathy and proteinuria of 1 g/d or greater, oral methylprednisolone was associated with an increased risk of serious adverse events, primarily infections. Although the results were consistent with potential renal benefit, definitive conclusions about treatment benefit cannot be made, owing to early termination of the trial. Trial Registration: clinicaltrials.gov Identifier: NCT01560052.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/tratamento farmacológico
Glucocorticoides/efeitos adversos
Infecção/etiologia
Metilprednisolona/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Método Duplo-Cego
Feminino
Taxa de Filtração Glomerular
Glomerulonefrite por IGA/complicações
Glucocorticoides/uso terapêutico
Seres Humanos
Falência Renal Crônica/etiologia
Falência Renal Crônica/mortalidade
Masculino
Metilprednisolona/uso terapêutico
Meia-Idade
Proteinúria/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glucocorticoids); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170802
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.9362


  8 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763530
[Au] Autor:O'Shaughnessy MM; Lafayette RA
[Ad] Endereço:Glomerular Disease Center, Stanford University School of Medicine, Palo Alto, California.
[Ti] Título:Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm.
[So] Source:JAMA;318(5):429-431, 2017 08 01.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Corticosteroides
Glomerulonefrite por IGA
[Mh] Termos MeSH secundário: Seres Humanos
Imunoglobulina A
Imunossupressores
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Immunoglobulin A); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.9359


  9 / 5443 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28698271
[Au] Autor:Guo WY; Zhu L; Meng SJ; Shi SF; Liu LJ; Lv JC; Zhang H
[Ad] Endereço:Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
[Ti] Título:Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy.
[So] Source:J Am Soc Nephrol;28(11):3175-3181, 2017 Nov.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:IgA nephropathy (IgAN) is characterized by infections followed by episodic gross hematuria. Deficiency of mannose-binding lectin (MBL) is associated with recurrent infection in many diseases, but controversy exists regarding the role of MBL in IgAN. Here, we measured variants and MBL levels in 749 patients with IgAN and 489 healthy controls. Overall, 5.2% (39 of 749) of patients with IgAN had MBL deficiency (MBL levels <100 ng/ml), among whom LYPB/LYPB and LXPA/LYPB were the predominant haplotypes (82%; 32 of 39). We found a nonlinear association between MBL levels and renal outcome in IgAN. Patients with IgAN and MBL deficiency had a higher incidence of prodromic infections and gross hematuria than those with sufficient MBL levels (100-3540 ng/ml). Moreover, MBL deficiency independently associated with poor renal outcome in IgAN after multiple adjustments (hazard ratio, 5.18; 95% confidence interval, 2.50 to 10.72; <0.001). Patients with high MBL levels (>3540 ng/ml) had more severe proteinuria and a higher proportion of crescents, although the association with IgAN progression did not reach statistical significance after adjustments. In conclusion, MBL deficiency and MBL excess may both have deleterious effects on IgAN progression, which suggests that MBL contributes to IgAN pathogenesis through multiple mechanisms.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/sangue
Lectina de Ligação a Manose/sangue
[Mh] Termos MeSH secundário: Adulto
Feminino
Glomerulonefrite por IGA/complicações
Seres Humanos
Masculino
Lectina de Ligação a Manose/deficiência
Erros Inatos do Metabolismo/etiologia
Prognóstico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mannose-Binding Lectin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2017010076


  10 / 5443 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28646076
[Au] Autor:Liu P; Lassén E; Nair V; Berthier CC; Suguro M; Sihlbom C; Kretzler M; Betsholtz C; Haraldsson B; Ju W; Ebefors K; Nyström J
[Ad] Endereço:Department of Physiology, Institute of Neuroscience and Physiology.
[Ti] Título:Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy.
[So] Source:J Am Soc Nephrol;28(10):2961-2972, 2017 Oct.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN ( =19) and controls ( =22). Using curated glomerular cell type-specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell-positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell-positive standard genes. Additionally, patient clinical parameters (serum creatinine values and eGFRs) significantly correlated with scores derived from the expression profile of mesangial cell-positive standard genes. Among patients grouped according to Oxford MEST score, patients with segmental glomerulosclerosis had a significantly higher mesangial cell-positive standard gene score than patients without segmental glomerulosclerosis. By investigating mesangial cell proteomics and glomerular transcriptomics, we identified 22 common pathways induced in mesangial cells by gd-IgA, most of which mediate inflammation. The genes, proteins, and corresponding pathways identified provide novel insights into the pathophysiologic mechanisms leading to IgAN.
[Mh] Termos MeSH primário: Glomerulonefrite por IGA/metabolismo
Células Mesangiais/metabolismo
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Células Cultivadas
Feminino
Perfilação da Expressão Gênica
Glomerulonefrite por IGA/genética
Seres Humanos
Masculino
Meia-Idade
Proteoma
Transcriptoma
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Proteome)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170625
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2016101103



página 1 de 545 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde